Want to see MMSI full AI Analyst Report?
MMSI Stock Chart & Stats
$68.17
$1.12(1.17%)
At close: 4:00 PM EST
$68.17
$1.12(1.17%)
Day’s Range― - ―
52-Week Range$59.74 - $94.75
Previous CloseN/A
Volume49.13K
Average Volume (3M)780.68K
Market Cap
$4.36B
Enterprise Value$4.47K
Total Cash (Recent Filing)$490.25M
Total Debt (Recent Filing)$821.56M
Price to Earnings (P/E)31.1
Beta0.51
Next Earnings
Jul 30, 2026EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.35
Shares Outstanding59,654,854
10 Day Avg. Volume703,400
30 Day Avg. Volume780,678
Financial Highlights & Ratios
PEG Ratio8.41
Price to Book (P/B)3.29
Price to Sales (P/S)3.44
P/FCF Ratio24.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$87.50Price Target Upside28.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)4.07
Revenue Forecast (FY)$1.62B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowConsistent, sizable FCF provides durable financial flexibility: funds for R&D, bolt-on M&A, shareholder returns or debt reduction. Operating cash ahead of earnings indicates quality profits, giving the company resilience through cycles and capacity to invest in higher-growth therapeutic initiatives.
Improving MarginsSustained margin expansion reflects better product mix, scale and pricing power, supporting long-term earnings quality. Higher gross and net margins enable reinvestment in commercial and R&D efforts for therapeutic products and provide a buffer against cost headwinds like tariffs.
Strategic M&A & Portfolio DiversificationTargeted acquisitions and a two-tier reporting model accelerate exposure to higher-growth therapeutic and oncology markets. Inorganic additions complement recurring disposables, deepen clinical use-cases, and can lift long-term growth and margin mix if integrations sustain cross-sell and scale benefits.
Bears Say
Sizeable Debt LoadAlthough leverage has improved, a large absolute debt stock limits strategic flexibility and raises susceptibility to margin or demand shocks. Interest and repayment commitments could constrain capital allocation for growth or acquisitions if free cash flow weakens or rates rise.
Tariff UncertaintySustained tariffs are a structural cost pressure that compresses gross margins unless offset by pricing or sourcing changes. Uncertainty around tariff persistence and refund prospects complicates planning, may force margin trade-offs, and can erode returns on new product investments.
End-market & OEM WeaknessMaterial OEM and regional demand softness suggests structural variability in procedure volumes and channel inventory. Persistent end-market weakness, especially in APAC, can slow organic recurring disposables revenue, reduce utilization-driven sales, and pressure near-term growth durability.
Merit Medical Systems News
MMSI FAQ
What was Merit Medical’s price range in the past 12 months?
Merit Medical lowest stock price was $59.74 and its highest was $94.75 in the past 12 months.
What is Merit Medical’s market cap?
Merit Medical’s market cap is $4.36B.
When is Merit Medical’s upcoming earnings report date?
Merit Medical’s upcoming earnings report date is Jul 30, 2026 which is in 5 days.
How were Merit Medical’s earnings last quarter?
Merit Medical released its earnings results on Apr 30, 2026. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.833 by $0.107.
Is Merit Medical overvalued?
According to Wall Street analysts Merit Medical’s price is currently Undervalued.
Does Merit Medical pay dividends?
Merit Medical does not currently pay dividends.
What is Merit Medical’s EPS estimate?
Merit Medical’s EPS estimate is 0.96.
How many shares outstanding does Merit Medical have?
Merit Medical has 59,654,854 shares outstanding.
What happened to Merit Medical’s price movement after its last earnings report?
Merit Medical reported an EPS of $0.94 in its last earnings report, beating expectations of $0.833. Following the earnings report the stock price went down -9.05%.
Which hedge fund is a major shareholder of Merit Medical?
Currently, no hedge funds are holding shares in MMSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merit Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.50 (28.36% Upside)
$87.50 (28.36% Upside)
Blogger Sentiment
Bullish
MMSI Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 6.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.18%
Trailing 12-Months
Company Description
Merit Medical
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
MMSI Stock 12 Month Forecast
Average Price Target
$87.50
▲(28.36% Upside)
Technical Analysis
ICU Medical
―
Lemaitre Vascular
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
2.69% Insiders
37.81% Mutual Funds
3.60% Other Institutional Investors
30.27% Public Companies and
Individual Investors